NCT06289673View on ClinicalTrials.gov

Identification of Necessary Information for Treatment Induction in Newly Diagnosed Acute Lymphoblastic Leukemia/Lymphoma

PHASE4RecruitingINTERVENTIONAL
Enrollment

850

Participants

Timeline

Start Date

December 26, 2024

Primary Completion Date

May 31, 2034

Study Completion Date

May 31, 2039

Conditions
Acute Lymphoblastic LeukemiaLymphoblastic LymphomaMixed Phenotype Acute Leukemia
Interventions
DRUG

Dexamethasone

Per mouth (PO) or intravenously (IV) once on Day 1 and PO or IV divided BID (every 12 hours) days 2-7

DRUG

Vincristine

Intravenously (IV) for 1 dose on Day 1 or 2

DRUG

Daunorubicin

Intravenously (IV) for 1 dose on Day 2 or 3 (T-ALL/ T-LLy/ MPAL only)

DRUG

Intrathecal triple therapy (methotrexate + hydrocortisone + cytarabine)

Intrathecal (Age adjusted) for 1 dose on Day 4 or 5 or 6

DRUG

Methotrexate

Given IT as part of Intrathecal triple therapy.

DRUG

Cytarabine

Given IT as part of Intrathecal triple therapy.

Trial Locations (3)

38105

RECRUITING

St. Jude Children's Research Hospital, Memphis

74136

RECRUITING

Saint Francis Children's Hospital, Tulsa

92123

RECRUITING

Rady Children's Hospital, San Diego

All Listed Sponsors
lead

St. Jude Children's Research Hospital

OTHER

NCT06289673 - Identification of Necessary Information for Treatment Induction in Newly Diagnosed Acute Lymphoblastic Leukemia/Lymphoma | Biotech Hunter | Biotech Hunter